Keynote Panel Discussion – Driving Clinical Success in Solid Tumor Settings
Time: 10:00 am
day: Day One
- What is the optimal cell type to tackle the solid tumor microenvironment
- What solid tumors should the field be targeting first, considering myeloid compartments and heterogeneity?
- Address acquired versus inherent resistance to immunotherapy
- Discuss how different modalities induce epitope spreading and the potential of this to overcome heterogeneity